Homogenization field trials

There is a serious problem in finite field theory. If even the weakest homogeneous electric field is applied and a very good basis set is used, we are bound to have some kind of catastrophe. It s a nasty word, but unfortunately it accurately reflects a mathematical horror that we are going to be exposed to after adding to the Hamiltonian operator = x with an electric field (here, x symbolizes the component of the dipole moment)." The problem is that this operator is unbound i.e., for a normalized trial function the integral may attain oo or —oo. Indeed, by... 

With the comprehensive research base that has developed in this area, if therapeutic peptides or proteins can be successfully and, to some extent, economically microencapsulated to produce a homogeneous and stable dmg delivery system, the potential for a successful system is unchallengeable. However, although many systems are in the process ofpreclinical and even early clinical trials, there are still many issues in this field that need to be addressed and resolved. Certain studies are performed with compounds that, for a number of reasons, are not viable commercially for oral delivery, usually because of related issues such as dose, cost, and encapsulation efficiency. Although many such studies are cited as proof of concept, it is extremely difficult to define a model peptide or protein with which to optimize a delivery system. Detailed scientific information on mechanisms of action is also lacking in many circumstances and, if available, would allow logical approaches to system optimization and ultimately potential widespread system application. 

---